Stay updated on Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial

Sign up to get notified when there's something new on the Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    The page has added helpful links related to adverse event reporting from the National Institute of Allergy and Infectious Diseases, while a notice about heavy traffic affecting NLM-NCBI services has been removed.
    Difference
    2%
    Check dated 2025-03-03T23:05:46.000Z thumbnail image
  4. Check
    30 days ago
    No Change Detected
  5. Check
    37 days ago
    Change Detected
    Summary
    The web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    0.6%
    Check dated 2025-02-10T16:09:21.000Z thumbnail image
  6. Check
    45 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.1 to 2.14.2.
    Difference
    0.0%
    Check dated 2025-02-03T11:20:35.000Z thumbnail image
  7. Check
    59 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.0 to 2.14.1.
    Difference
    0.0%
    Check dated 2025-01-20T03:46:52.000Z thumbnail image
  8. Check
    66 days ago
    Change Detected
    Summary
    The website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.
    Difference
    0.1%
    Check dated 2025-01-12T23:25:04.000Z thumbnail image
  9. Check
    95 days ago
    Change Detected
    Summary
    The study has officially closed to accrual and follow-up was completed on October 18, 2023, with new details on genotypic and phenotypic measures of resistance to integrase, protease, and reverse transcriptase genes, while previous ongoing study references and interim data summaries have been removed.
    Difference
    10%
    Check dated 2024-12-15T00:24:50.000Z thumbnail image

Stay in the know with updates to Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial page.